Novel minor groove binders cure animal African trypanosomiasis in an<em> in vivo</em> mouse model (Publications)
been used for decades, have now lost efficacy in some places because of the emergence of resistant parasites. Consequently, the need for new chemotherapies is urgent. Here, we describe a structurally distinct
Malaria Trends in DRC (News)
https://www.swisstph.ch/en/news/20170901-malaria-trends-drc
malaria cases after the introduction of rapid diagnostic tests which detect evidence of malaria parasites in human blood. Population coverage across DRC was improved through mass distribution of long-lasting
Discovery of an orally active nitrothiophene-based antitrypanosomal agent (Publications)
Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei gambiense and rhodesiense, is a parasitic disease endemic to sub-Saharan Africa. Untreated cases of HAT can be severely debilitating and fatal
Medical Services (Page)
https://www.swisstph.ch/en/about/dir/medical-services
(FOPH), provides reference diagnosis for malaria and confirmatory diagnosis for other non-endemic parasitic diseases as part of the surveillance concept for notifiable infectious diseases. Centre for Tropical
Repurposing a library of human cathepsin L ligands: identification of macrocyclic lactams as potent rhodesain and <em>trypanosoma brucei... (Publications)
Rhodesain (RD) is a parasitic, human cathepsin L (hCatL) like cysteine protease produced by Trypanosoma brucei ( T. b.) species and a potential drug target for the treatment of human African trypanosomiasis
<em>Hippeastrum reticulatum </em>(Amaryllidaceae): alkaloid profiling, biological activities and molecular docking (Publications)
(6alpha-hydroxymaritidine and 6beta-hydroxymaritidine) showed low activity against all protozoan parasites tested and weak AChE-inhibitory activity. Finally, a molecular docking analysis of AChE and BuChE
Lead optimization of a pyrrole-based dihydroorotate dehydrogenase inhibitor series for the treatment of malaria (Publications)
target-based DHODH screen. Compounds with nanomolar potency versus Plasmodium DHODH and Plasmodium parasites were identified with good pharmacological properties. X-ray studies showed that the pyrroles bind
Structure–activity relationship studies and <em>Plasmodium</em> life cycle profiling identifies pan-active N-aryl-3-trifluoromethyl... (Publications)
potent in vitro activities against the asexual blood, liver and gametocyte stages of the Plasmodium parasite with no cross-resistance to chloroquine. Frontrunner lead compounds with good in vitro absorption
Induced pluripotent stem cell-derived human macrophages as an infection model for <em>Leishmania donovani</em> (Publications)
The parasite Leishmania donovani is one of the species causing visceral leishmaniasis in humans, a deadly infection claiming up to 40,000 lives each year. The current drugs for leishmaniasis treatment
<em>In vitro</em> efficacy of dicationic compounds and mefloquine enantiomers against <em>Echinococcus multilocularis</em> metacestodes (Publications)
recently validated assay based on the release of functional phosphoglucose isomerase (PGI) from dying parasites, the activities of 26 dicationic compounds and of the (+)- and (-)-erythro-enantiomers of mefloquine
